Finance & Capital Markets
-
Biotech Cash Management With Allan Shaw
8/2/2023
It’s been said that clinical trials are where emerging biotechs go to die. If the science doesn't kill quickly, poor cash management will slowly. On this week's episode of the Business of Biotech, our favored biotech finance management maven, Allan Shaw, offers pointed advice on stretching cash runways for the long run.
-
Biotech C-Suite Construction With Allan Shaw
10/13/2024
Allan Shaw is back with us this week to dig into the complexities of strategic hiring in biotech. If you're growing a biotech in these volatile times, this episode of the Business of Biotech offers veteran insight you won't want to miss.
-
Serial Success With Triumvira's Rob Williamson
3/10/2024
Rob Williamson's mind and hands have shaped more than 20 biotech startups, leading some to IPO and landing others firmly in Big Bio through acquisition by companies like Merck. Learn secrets to his serial success on this week's Business of Biotech podcast.
-
Embracing Biotech Chaos With Memo's Erik van den Berg
9/8/2024
Erik van den Berg is CEO and board member at Memo Therapeutics, and he's a student of biotech chaos. In fact, he's been embracing it with intention for the past 30 years. On this episode of the Business of Biotech, he walks us through the management of that chaos in specific detail.
-
BoB@JPM: Rick Modi, Affinia Therapeutics
3/5/2025
The latest in our series of Business of Biotech podcasts recorded in-person at JPM in San Francisco features an inspiring conversation with Affinia Therapeutics CEO Rick Modi. Modi shares on how his upbringing in Kenya shaped his adversity-embracing worldview, and how that worldview contributes to his biotech leadership
-
The Implications Of China's Growing Biotech Industry With Allan Shaw
4/16/2025
Business of Biotech MVP Allan Shaw is back to talk about the rise of China's biotech sector, and its evolution from fast follower to global innovation powerhouse.
-
Clinical Leadership with Cue Biopharma's Anish Suri, Ph.D. & Dan Passeri, J.D.
10/20/2023
On a road trip to Boston, the Business of Biotech caught up with podcast alum Dan Passeri, J.D., CEO at Cue Biopharma, and enjoyed a two-for-one with CSO and President Anish Suri, Ph.D. at Cue's headquarters just feet below the Auerbach Center. Among other things, we discussed the duo's complementary leadership approach as the company takes multiple candidates into the clinic, why Passeri leans into his biotech legal background almost every day he's at work, why Cue's discretely targeted IL-2 approach eliminates the absurdity of early IL-2 failures, and a whole lot more.
-
A $1B AI Bet With Foresite Labs' Vik Bajaj, Ph.D.
12/15/2024
This past spring, Xaira Therapeutics launched with $1 billion in backing, a who's-who mashup of Silicon Valley and biopharma stars led by Marc Tessier-Lavigne in the C-suite, and a mission to develop AI-generated drugs. On this week's episode of the Business of Biotech, we're digging into the company's origin story and its place on the greater techbio landscape with one of the men bearing responsibility for Xaira's launch.
-
Managing Mergers With Sail's Guillaume Pfefer, Ph.D
2/15/2024
You might be aware that Sail Biomedicines was just formed up in Q4 of last year, the product of Flagship Pioneering’s decision to merge Senda Biosciences and Laronde, two of its programmable medicine platform companies. What you likely haven’t heard is the inside story on how the merger was executed, how the two companies are integrating their talent, IP, and resources, and what Sail Biomedicines CEO Dr. Guillaume Pfefer and team are currently doing to take the fruits of the company’s platform into the clinic.
-
Building On Pandemic Progress With Barinthus Biotherapeutics' Bill Enright
10/27/2024
It sure seems like Bill Enright has a knack for making big moves at inopportune times, then turning the expected outcome on its ear. For example, he signed on as CEO at Altimmune when the company was struggling mightily. Enright had a turnaround plan in hand, but as he was in the thick of a non-deal road show to execute said plan, Lehmen Brothers collapsed. On this episode of the Business of Biotech, we'll learn how he flipped the script and other harrowing tales from the trenches.